Synergy appoints Dr Laura Barrow VP of clinical operations
This article was originally published in Scrip
Synergy Pharmaceuticals, a New York-based developer of drugs to treat gastrointestinal disorders and diseases, has appointed Dr Laura Barrow vice-president of clinical operations. In this newly created position, she will be responsible for Synergy's clinical programmes, including the Phase II/III study of the company's lead drug candidate, plecanatide. Dr Barrow has more than 25 years' pharmaceutical industry experience, having most recently served as worldwide head of clinical and regulatory standard operating procedures at Pfizer. She also spent seven years in clinical research at Roche, and 17 years in project management and organisational effectiveness at Bristol-Myers Squibb.